key: cord-0758853-xqsblxyh
authors: Corti, C.; Antonarelli, G.; Scotté, F.; Spano, J.P.; Barrière, J.; Michot, J.M.; André, F.; Curigliano, G.
title: Seroconversion rate after vaccination against COVID-19 in cancer patients - a systematic review
date: 2021-10-28
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.10.014
sha: 9cd7e7fe4a347409903d51377843014fdc657906
doc_id: 758853
cord_uid: xqsblxyh

BACKGROUND: Coronavirus disease 2019 (COVID-19) has affected more than 210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer were mostly excluded from vaccine candidates’ clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in patients with cancer (PsC). PATIENTS AND METHODS: All prospective studies that evaluated safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the second dose as the primary endpoint, when available. RESULTS: Vaccination against COVID-19 for PsC seems overall safe and immunogenic after well-conducted vaccinations schedules. Yet, the seroconversion rate remains lower, lagged or both compared to the general population. Patients with hematologic malignancies, especially those receiving B cell depleting agents in the last 12 months are the most at risk of poor seroconversion. CONCLUSION: A tailored approach to vaccination may be proposed to PsC, especially on the basis of the type of malignancy and of the specific oncologic treatments received.

Since the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 112 coronavirus disease 2019 (COVID-19) has affected more than 210 million people worldwide (1) . 113

Besides oxygen therapy and positive pressure ventilation, glucocorticoids, especially 114 dexamethasone, showed a mortality benefit in patients requiring respiratory support (2) . Despite 115 different therapeutic approaches being investigated, an optimal treatment for COVID-19 remains 116 uncertain (Figure 1 ) (3-5). 117

Nevertheless, global efforts have established an effective vaccine strategy and, because history of 118 cancer is linked to higher mortality rates due to COVID-19, an effective vaccine coverage is crucial 119 in this population (6-13). However, clinical trials investigating COVID-19 vaccine candidates mostly 120 excluded patients with cancer (PsC). So, international COVID-19 vaccination guidelines for this 121 population were initially based on expert opinions, on studies designed to test other vaccines and 122 on initial real-world data reports (14, 15) . 123

This systematic review aims to investigate the current available evidence about immunogenicity of 124 COVID-19 vaccines currently administered to PsC. 125

We assessed the quality of included studies using the Quality Assessment Tool for Observational

The former was administered in 9 clinical studies (25%), whereas the latter was evaluated only in vaccines were administered (35). After the first dose, patients with a diagnosis of myelofibrosis (MF) 249 (n = 9) had significantly higher post-vaccine anti-Spike IgG half maximal effective concentration 250 (EC50) as well as neutralizing Ab inhibitory dose (ID)50 titers, compared to patients with other MPN 251 subtypes (20). Seroconversion measured >14 days after a single dose was only 58%, that is 252 significantly lower than the one observed in health-care professionals (HCPs) of similar age (97%). 253

The median anti-spike Ab titer was also significantly lower in MPN 

Another study including 95 patients with solid cancer and 66 healthy controls reported a 304 seroconversion rate of 87% and 100% in patients and controls, respectively, after a median of 123 305 days from the second vaccination. However, a significantly lower median titer levels in PsC was 306 found, in comparison with the control group (417 AU/mL versus 1220 AU/mL, p < 0.001) (42). In an 307 exploratory multivariate analysis, the co-administration of CT plus immunotherapy (IO) or of IO plus 308 a biological agent resulted the only variable associated with lower IgG titers. A recent pooled analysis 309 including 223 PsC with solid tumors highlighted a higher seroconversion rate (94%), with significantly 310 lower anti-Spike Abs, compared to healthy controls, irrespective of the assay used (19, 28, 43). 311 312

A major unanswered question for PsC is whether vaccine immunogenicity is impacted by the 314 concomitant use of specific drugs. Initial findings from the VOICE trial, focusing on solid tumors, 315

have been recently presented (44). Among patients receiving IO, CT and CT-IO, anti-Spike (S1) IgG 316 seroconversion rates were 99.3%, 97.4% and 100%, respectively. As the authors established a cut-317 off of 300 BAU/mL for adequate Ab response, seroconversion rates after two vaccine doses dropped 318 to 93.1%, 83.8% and 88.8%, for patients receiving IO, CT and CT-IO, respectively (44). Thus, a 319 significant minority of patients does not develop an adequate Ab response (6.9%, IO; 16.2%, CT; 320 11.2%, CT-IO). Few other studies focused on individual agents to fully elucidate any potential 321 interaction with the ability to mount a protective immune response. Emerging data are clarifying that, 322 in general, the protective role of two vaccine doses for PsC on certain active treatments may be 323 suboptimal (Figure 3) In a recent study, post-vaccination seroconversion rates in patients receiving ET (n = 47) resulted 327 high in comparison with other active treatments, reaching a 100% seropositivity rate (p = 0.04) (21). and of the specific oncologic treatment received (Figure 4) under treatment with B cell depleting agents, CD19-directed CAR-T cell therapies and HCT 505 recipients showed very low seroconversion rates from vaccination, prompting concern that they are 506 likely to have poor protection against COVID-19. A third vaccine dose may be proposed to such 507 immunocompromised categories, possibly considering a time window consistent with the emerging 508 evidence of an acceptable serological response between 9 and 12 months, after completing 509 treatment (Figure 4) (20, 38, 46, 89) . A similar approach may be warranted for individuals with active 510 CLL and older patients with MM, although a case-by-case management is recommended (29, 30, 511 41). Findings from prospective clinical trials with a longer follow-up will further elucidate how to tailor 512 vaccination in special populations (108-111). 513

A major obstacle to achieve herd immunity is vaccine hesitancy (92). In the specific population of 514

PsC, vaccine acceptance is generally higher than in other patient populations (49, 97, 98). In an 515 Investigated strategies against SARS-CoV-2 Targeting Full-text consulted for eligibility (n = 55) Excluded (n=22) -case series (n = 3); -overlapping results (n = 3); -cancer pts not included (n = 2); -no efficacy data (n = 3); -retrospective studies (n = 11).

-meta-analysis (n = 2); -case report (n = 45); -not SARS-CoV-2 (n = 102); -narrative reviews & commentaries (n = 1377); -other (n =26);

COVID-19) pandemic. Numbers at a glance

Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-584 19: A Meta-analysis

Tocilizumab in patients admitted 586 to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-587 label

Baricitinib plus Standard of Care 589 for Hospitalized Adults with COVID-19

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Clinical impact 593 of COVID-19 on patients with cancer (CCC19): a cohort study

Mortality in 607 patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 608 studies

A systematic review and meta-analysis: the effect of active 610 cancer treatment on severity of COVID-19

COVID-19 in 612 patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, 613 cohort study

Commentary: SARS-CoV-2 vaccines and cancer patients

CoV-2 vaccines for cancer patients: a call to action

Immunogenicity 619 and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Impaired 622 response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving 623 ruxolitinib

Seroconversion rates following COVID-19 vaccination among patients with cancer

Immune checkpoint inhibitors 637 increase T cell immunity during SARS-CoV-2 infection

Serological 639 response to COVID-19 vaccination in patients with cancer older than 80 years

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in 642 patients with haematological malignancies in Lithuania: a national prospective cohort study

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for 646 patients with cancer: interim analysis of a prospective observational study

1557O -Adaptive 649 immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study

Low neutralizing antibody responses against SARS-CoV-2 in older patients 661 with myeloma after the first BNT162b2 vaccine dose

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma 664

Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers (Basel)

testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals 668 with multiple myeloma

Highly 670 variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in 671 patients with multiple myeloma

Impaired antibody 676 response to COVID-19 vaccination in patients with chronic myeloid neoplasms

mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Safety and 691 efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia

Antibody responses after 694 first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

High seroconversion rate 699 but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated 700 with chemotherapy for solid cancers. Ann Oncol. 2021. 701 44. van der Veldt AAM

COVID-19 vaccination: the VOICE for patients with cancer

Reduced SARS-CoV-2 infection and 705 death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

Current perspectives for SARS-CoV-2 vaccination 716 efficacy improvement in patients with active treatment against cancer

B cell reconstitution 719 after rituximab treatment of lymphoma recapitulates B cell ontogeny

SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA 723 COVID-19 vaccine in haematological and oncological patients

Brief Communication: humoral and 725 cellular responses after a third dose of BNT162b2 vaccine in patients with lymphoid malignancies

Research Square -Nature Portfolio2021

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic 729 malignancies

Immunomodulatory Roles of Cell Cycle Regulators

neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 734 inhibitors. The Breast

Humoral 744 and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer

Cell. 2021. 746 60. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 -Studies Needed

Adaptive immunity to SARS-CoV-2 and COVID-19

Early induction of 754 functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in 755 COVID-19 patients

SARS-CoV-2 Accessed for up to 8 months after infection

A correlate of protection for SARS-CoV-2 vaccines is urgently needed

BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home 762

Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant 763 Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against

Hospitalizations Among Adults

ESMO Statements 775 for Vaccination against COVID-19 in patients with cancer

Preexisting 778 and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients 784 with minimal serologic response after two vaccine doses

CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Safety and 789 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral 790 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

The efficacy of 799 accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer 800 patients receiving chemotherapy

Phase I/II study of 802 COVID-19 RNA vaccine BNT162b1 in adults

UK: OCTAVE DUO -New study to test third COVID-19 vaccine for people with 806 weakened immune systems

Examining the 809 immunological effects of COVID-19 vaccination in patients with conditions potentially leading to 810 diminished immune response capacity -the OCTAVE Trial

A Third Dose of SARS-CoV-813

Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant 814

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

CoV-2 vaccination among French patients with cancer: a cross-sectional survey

The first report on 856 coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early 857 data from a single-institute survey

Parental Vaccine Hesitancy: A Cluster Randomized Trial

Adherence to COVID-19 vaccines in cancer patients: 861 promote it and make it happen!

Effects of a 863 large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster 864 randomized controlled trial

COVID-19 vaccination for 866 cancer patients: Medical and ethical need

Immune responses to COVID-19 vaccines in patients with cancer: 868 Promising results and a note of caution

Neutralizing 870 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

J o u r n a l P r e -p r o o f